Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia.

CONTEXT: Available therapies for type 2 diabetes mellitus (T2DM) do not adequately control glycemia in the long term as they do not address the issue of declining beta cell function and do not impact positively on weight or cardiovascular concerns associated with the disease. AIMS: To measure changes in hemoglobin A1c, weight, and hypoglycemia after the addition of liraglutide to 3 therapeutic regimens of patients with T2DM. SETTINGS AND DESIGN: An observational cohort study that was implemented in Al-Wazarat Health Center in Riyadh, Saudi Arabia. METHODS AND MATERIALS: The study included 38 T2DM patients who were screened for initiation of liraglutide in combination with their treatment regimens; sulphonylurea, sulphonylurea with basal insulin (glargine), and multiple daily injections of insulin. The cohort was followed for 12 months, and the liraglutide was started with 0.6 mg dose that escalated to 1.2 and 1.8 mg. Glycemic level and weight were measured 3 times, whereas hypoglycemia was measured 2 times. STATISTICAL ANALYSIS USED: Quantitative continuous paired data were compared using a paired -test and the nonparametric Wilcoxon signed rank test. RESULTS: There was a statistically significant reduction of hemoglobin A1c with 1.2 mg dose (mean difference = 0.84%, = 0.003). There were no statistically significant differences regarding the effect of liraglutide in addition to the 3 treatment regimens on patients' weight ( = 0.08, 0.472, 0.08, respectively). Regarding hypoglycemia, liraglutide has showed minimal effect. CONCLUSIONS: Sustained effect of liraglutide on glycemic control in patients with T2DM without any major hypoglycemic episodes.